Message from the Editor in Chief

Main Article Content

Mitch Levine


In the current issue of the Canadian Journal of General Internal Medicine (CJGIM), McIntyre and Seifer have identified the clinical benefits of cardiac resynchronization therapy (CRT) for patients with heart failure and conduction abnormalities (QRS > 130 msec). These benefits include a reduction in mortality and hospitalization. They also point out that the individual probability of benefiting from a CRT is variable amongst patients. For example, the larger the QRS interval the greater the potential benefit.
Abstract 423 | PDF Downloads 190 HTML Downloads 217


1. Bernard ML, Gold MR. Economic Implications and Cost-effectiveness of Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy. Heart Fail Clin. 2011 Apr;7(2):241-50, ix. doi: 10.1016/j.hfc.2010.12.007.

2. Nichols CI, Vose JG1, Mittal S. Incidence and Costs Related to Lead Damage Occurring Within the First Year After a Cardiac Implantable Electronic Device Replacement Procedure. J Am Heart Assoc. 2016 Feb 12;5(2). pii: e002813. doi: 10.1161/JAHA.115.002813.